In this manuscript the authors show that miRNA-138 (miR-138) modulates osteogenic differentiation of human stromal (mesenchymal) stem cell (hMSC). These findings suggest that pharmacological inhibition of miR-138 by antimiR-138 could represent a therapeutic strategy for enhancing bone formation in vivo.
Eskildsen T, Taipaleenmäki H, Stenvang J, Abdallah BM, Ditzel N, Nossent AY, et al
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6139-44. Epub 2011 Mar 28.